MIR664A

Summary

MIR664A (microRNA 664a, HGNC:35370) is a microRNA gene on chromosome 1q41.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 100302234 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:35370
Approved symbol	MIR664A
Name	microRNA 664a
Location	1q41
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-664
Ensembl gene	ENSG00000281696
Ensembl biotype	miRNA
Entrez	100302234
RNAcentral	URS000075B7FD — ncRNA, 82 nt, 5 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000626086

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000626086 — 1 exons

Exon	Start	End
ENSE00003764771	220200538	220200619

Expression profiles

Bgee: expression breadth broad, 63 present calls, max score 77.85.

Top tissues by expression

63 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
placenta	UBERON:0001987	77.85	gold quality
endometrium	UBERON:0001295	77.16	gold quality
calcaneal tendon	UBERON:0003701	77.04	gold quality
blood	UBERON:0000178	76.12	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	72.53	gold quality
islet of Langerhans	UBERON:0000006	71.78	gold quality
liver	UBERON:0002107	71.40	gold quality
kidney	UBERON:0002113	71.15	gold quality
stomach	UBERON:0000945	71.07	gold quality
gastrocnemius	UBERON:0001388	70.62	gold quality
heart	UBERON:0000948	68.25	gold quality
nucleus accumbens	UBERON:0001882	67.98	gold quality
right atrium auricular region	UBERON:0006631	67.77	gold quality
left coronary artery	UBERON:0001626	67.07	gold quality
body of stomach	UBERON:0001161	66.66	gold quality
thoracic aorta	UBERON:0001515	66.49	gold quality
skin of abdomen	UBERON:0001416	66.46	gold quality
ascending aorta	UBERON:0001496	66.36	gold quality
tibial artery	UBERON:0007610	65.53	gold quality
body of pancreas	UBERON:0001150	65.39	gold quality
lower esophagus muscularis layer	UBERON:0035833	65.36	gold quality
putamen	UBERON:0001874	65.05	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	64.95	gold quality
esophagus mucosa	UBERON:0002469	64.51	gold quality
subcutaneous adipose tissue	UBERON:0002190	64.50	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	64.43	gold quality
transverse colon	UBERON:0001157	64.41	gold quality
body of uterus	UBERON:0009853	64.00	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	63.63	gold quality
minor salivary gland	UBERON:0001830	63.46	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.77

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 17)

• Data indicate that expression of miR-1260, -26a, -335*, -576-3p, -628-3p and -664 were consistently dysregulated in both whole blood and H1N1 infected cells. (PMID:24116168)
• miR-664 play an important role in suppressing proliferation of cactaneous malignant melanoma cells and present a novel mechanism of miR-mediated direct suppression of PLP2 expression in cancer cells. (PMID:26287415)
• miR-664 functions as an oncogene miRNA and has an important role in promoting human osteosarcoma cell proliferation by suppressing FOXO4 expression. (PMID:26463624)
• The results suggest that miR-664 functions as an oncogene miRNA and has an important role in promoting human osteosarcoma cell invasion and migration by suppressing SOX7 expression. (PMID:26515813)
• Increased miR664a expression is associated with non-small cell lung cancer in comparison to chronic obstructive pulmonary diseases. (PMID:26672767)
• Interaction between MEG3 and miR-664a affected migration of osteosarcoma cells. miR-664a could bind to lncRNA MEG3 and change its expression in osteosarcoma. miR-664a functions as an onco-microRNA in osteosarcoma via inhibition of MEG3. (PMID:28669734)
• The aim of our retrospective study was to evaluate the association of miR-126-3p, miR-126-5p and miR-664-3p tumour expression levels with outcomes of patients with metastatic colorectal cancer treated with bevacizumab.the results of this study suggest that the expression of miR-126-3p in the tumour tissue was associated with outcome of metastatic colorectal cancer patients treated with bevacizumab (PMID:28714375)
• High miR664 expression is associated with neuroblastoma. (PMID:29341475)
• miR-664a-3p was downregulated in Obstructive Sleep Apnea and Carotid intima-media thickness groups compared with the control group.The demonstrated potential of circulating miR-664a-3p as a noninvasive marker of Atherosclerosis. (PMID:29419680)
• miR-664 is downregulated in BC tissues and cell lines. In addition, miR-664 restricts proliferation and migration of BC cells. Moreover, IRS1 is validated as a direct target of miR-664 in BC. (PMID:29495974)
• miR-664 was remarkably high in cutaneous squamous cell carcinomas (cSCC) patient specimens and cSCC cell lines. Study identified IRF2 as a direct downstream target of miR-664. Knockdown of IRF2 reverses pro-tumorigenesis phenotype of miR-664; whereas IRF2 over-expression inhibits miR-664 tumorigenesis in cSCC. Together, it revealed miR-664 functions as an oncogene in cSCC via suppression of IRF2. (PMID:31138473)
• identified miR-664a-5p-HMGA2 pathway expands the osteogenic differentiation of human bone marrow-derived mesenchymal stem cells (BMSCs), may provide deeper insights into the regulation of this differentiation, and can point to new effective methods for treating osteoporosis (PMID:31630797)
• The present study validated significant upregulation of hsa-miR-664a-3p in COPD patients, and its target gene FHL1 was downregulated and positively correlated with FEV1/FVC%; both hsa-miR-664a-3p and FHL1 could be regulated by cigarette smoke extract. Results of bioinformatic analyses and expanded validation suggest that the axis from hsa-miR-664a-3p to FHL1 might play a key role in cigarette smoke-induced COPD, and the e (PMID:31632001)
• The long noncoding RNA OTUD6B-AS1 enhances cell proliferation and the invasion of hepatocellular carcinoma cells through modulating GSKIP/Wnt/beta-catenin signalling via the sequestration of miR-664b-3p. (PMID:32682012)
• Downregulation of ARMC8 promotes tumorigenesis through activating Wnt/beta-catenin pathway and EMT in cutaneous squamous cell carcinomas. (PMID:34016486)
• Novel Insights into MEG3/miR664a-3p/ADH4 Axis and Its Possible Role in Hepatocellular Carcinoma from an in Silico Perspective. (PMID:36553522)
• miR-664a-5p promotes experimental membranous nephropathy progression through HIPK2/Calpain1/GSalpha-mediated autophagy inhibition. (PMID:38186203)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.